SCHEMBL999693

SCHEMBL999693

NOC(=O)c1cccc(N)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PBRM1 Q86U86 1/20 0.57
NPC1 O15118 1/20 0.49
MITF O75030 1/20 0.49
LMNA P02545 1/20 0.49
POLB P06746 1/20 0.49
F2 P00734 1/20 0.48
PLG P00747 1/20 0.48
PRSS1 P07477 1/20 0.48
PRSS2 P07478 1/20 0.48
PRSS3 P35030 1/20 0.48
CHRNB2 P17787 1/20 0.48
CHRNA4 P43681 1/20 0.48
DDX3X O00571 1/20 0.47
ADRB2 P07550 2/20 0.47
ADRB1 P08588 2/20 0.47
ADRB3 P13945 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
HSD17B10 Q99714 1/20 0.45
ALDH1A1 P00352 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1064314 0.87 ATM (0.46) LMNAF2SMN1; SMN2ALDH1A1TDP1
SCHEMBL8003710 0.85 PBRM1 (0.59) PBRM1NPC1MITFLMNAPOLB
SCHEMBL9510637 0.83 PBRM1 (0.57) PBRM1NPC1MITFLMNAPOLB
SCHEMBL28045479 0.82 PBRM1 (0.55) PBRM1NPC1MITFLMNAPOLB
SCHEMBL28539853 0.82 PBRM1 (0.55) PBRM1NPC1MITFLMNAPOLB
SCHEMBL5033580 0.82 PBRM1 (0.55) PBRM1NPC1MITFLMNAPOLB
SCHEMBL29836775 0.82 LOXL2 (0.61) PBRM1NPC1MITFLMNAPOLB
SCHEMBL13399668 0.82 PBRM1 (0.55) PBRM1NPC1MITFLMNAPOLB
SCHEMBL29071827 0.82 PBRM1 (0.55) PBRM1NPC1MITFLMNAPOLB
SCHEMBL134170 0.82 LOXL2 (0.61) PBRM1NPC1MITFLMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7868135-B2 Compositions of lipopeptide antibiotic derivatives and methods of use thereof BIOWEST THERAPEUTICS INC. (CA) 2011-01-11 US disclosed
EP-2147925-A1 Compositions of lipopeptide antibiotic derivatives and methods of use thereof MIGENIX INC. (CA) 2010-01-27 EP disclosed
US-20080171783-A1 COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE MIGENIX INC. (CA) 2008-07-17 US disclosed
WO-2008080223-A1 COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE MIGENIX INC. (CA) 2008-07-10 WO disclosed
US-20070021434-A1 NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF MIGENIX INC. (CA) 2007-01-25 US disclosed
US-7083833-B2 Photoalignment materials and liquid crystal display fabricated with such photoalignment materials LG.PHILIPS LCD CO., LTD. (KR) 2006-08-01 US disclosed
US-20050153876-A1 Compositions of lipopeptide antibiotic derivatives and methods of use thereof MIGENIX INC. (CA) 2005-07-14 US disclosed
US-20040219307-A1 Photoalignment materials and liquid crystal display fabricated with such photoalignment materials LG DISPLAY CO., LTD. (KR) 2004-11-04 US disclosed
US-6793987-B2 FOR USE IN FLAT PANEL DISPLAY DEVICES, INCLUDING LIQUID CRYSTAL DISPLAY DEVICES, ARE WIDELY USED IN CELLULAR PHONES, NOTEBOOK COMPUTERS, AND WIDE SCREEN TELEVISIONS LG.PHILIPS LCD CO., LTD. (KR) 2004-09-21 US disclosed
US-6770335-B2 FOR USE IN FLAT PANEL DISPLAY DEVICES, INCLUDING LIQUID CRYSTAL DISPLAY DEVICES, ARE WIDELY USED IN CELLULAR PHONES, NOTEBOOK COMPUTERS, AND WIDE SCREEN TELEVISIONS LG.PHILIPS LCD CO., LTD. (KR) 2004-08-03 US disclosed
US-20020054966-A1 Photoalignment materials and liquid crystal display fabricated with such photoalignment materials LG DISPLAY CO., LTD. (KR) 2002-05-09 US disclosed
US-20020054967-A1 Photoalignment materials and liquid crystal display device and method for fabricating the same with said materials LG DISPLAY CO., LTD. (KR) 2002-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021434-A1 NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF HAVCR2, ADAR, NSUN2 PBRM1 4746/4885NPC1 83/4885MITF 3498/4885
US-20050153876-A1 Compositions of lipopeptide antibiotic derivatives and methods of use thereof NRDC, NOD2, NGLY1 PBRM1 3919/4885NPC1 1821/4885MITF 1546/4885
US-20080171783-A1 COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE POLQ, POLI, POLH PBRM1 738/4885NPC1 2526/4885MITF 2345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.